Anthrax Infection

IND application submitted to FDA for ToxBlox anthrax infection treatment

Published in Biotech Business Week, April 26th, 2004

PharmAthene, Inc., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate human clinical trials of ToxBlox, a novel protein, initially known as dominant negative inhibitor (DNI), being developed as a potent therapeutic agent to combat the lethal effects of anthrax toxin.

PharmAthene plans to initiate a phase I placebo-controlled, dose escalation clinical trial to evaluate the safety, tolerability and pharmacokinetics of ToxBlox in healthy adult volunteers.

Submission of this IND by PharmAthene is the first step in the process of obtaining approval for ToxBlox as a treatment for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry